Functional cure for chronic hepatitis B: accessibility, durability, and prognosis
- PMID: 34082765
- PMCID: PMC8176700
- DOI: 10.1186/s12985-021-01589-x
Functional cure for chronic hepatitis B: accessibility, durability, and prognosis
Abstract
Hepatitis B surface antigen (HBsAg) clearance is regarded as the ideal endpoint for antiviral treatment in terms of drug withdrawal safety and improvements in prognosis. However, the overall rate of HBsAg clearance is low and differs based on treatment method and course. The recent application of combined and extended treatment strategies have improved the HBsAg clearance rate, and several patients achieved HBsAg clearance in clinical treatment. In addition, the durability of and clinical outcomes after HBsAg clearance have become the focus of both researchers and clinicians. This article reviews HBsAg clearance in terms of accessibility, durability, improvements in prognosis and relevant advances.
Keywords: HBsAg clearance; Hepatitis B virus; Prognosis.
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
[Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].Zhonghua Gan Zang Bing Za Zhi. 2018 Nov 20;26(11):813-818. doi: 10.3760/cma.j.issn.1007-3418.2018.11.002. Zhonghua Gan Zang Bing Za Zhi. 2018. PMID: 30616314 Chinese.
-
Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.J Gastroenterol Hepatol. 2012 Mar;27(3):481-6. doi: 10.1111/j.1440-1746.2011.06970.x. J Gastroenterol Hepatol. 2012. PMID: 22098411
-
Extended duration therapy regimens based on Pegylated interferon for chronic hepatitis B patients focusing on hepatitis B surface antigen loss: A systematic review and meta-analysis.Infect Genet Evol. 2020 Nov;85:104492. doi: 10.1016/j.meegid.2020.104492. Epub 2020 Aug 5. Infect Genet Evol. 2020. PMID: 32763441
-
Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study.J Gastroenterol. 2013 Aug;48(8):930-41. doi: 10.1007/s00535-012-0688-7. Epub 2012 Oct 12. J Gastroenterol. 2013. PMID: 23065021
-
[Predictive factors for HBsAg-negative seroconversion in chronic hepatitis B after antiviral therapy].Zhonghua Gan Zang Bing Za Zhi. 2024 Feb 20;32(2):186-192. doi: 10.3760/cma.j.cn501113-20231213-00278. Zhonghua Gan Zang Bing Za Zhi. 2024. PMID: 38514272 Review. Chinese.
Cited by
-
The Connection between MiR-122 and Lymphocytes in Patients Receiving Treatment for Chronic Hepatitis B Virus Infection.Microorganisms. 2023 Nov 8;11(11):2731. doi: 10.3390/microorganisms11112731. Microorganisms. 2023. PMID: 38004743 Free PMC article.
-
The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance.Hum Vaccin Immunother. 2023 Dec 31;19(1):2161254. doi: 10.1080/21645515.2022.2161254. Epub 2023 Jan 22. Hum Vaccin Immunother. 2023. PMID: 36683193 Free PMC article.
-
Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study.Front Med (Lausanne). 2024 Dec 4;11:1489671. doi: 10.3389/fmed.2024.1489671. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39697201 Free PMC article.
-
B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection.Adv Ther. 2023 Sep;40(9):4101-4110. doi: 10.1007/s12325-023-02531-z. Epub 2023 Jul 1. Adv Ther. 2023. PMID: 37393402 Free PMC article. Clinical Trial.
-
Factors Positively Correlated with Hepatitis B Surface Antigen Seroconversion in Chronic Hepatitis B.J Pers Med. 2024 Apr 5;14(4):390. doi: 10.3390/jpm14040390. J Pers Med. 2024. PMID: 38673017 Free PMC article.
References
-
- EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources